Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the pricing of concurrent, separate underwritten offerings of (i) 55.9M shares of its common ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE